| Index | Ligand Name | Structure | PDB code | Compound Potency nM |
| 1 | dqx | Crystal Structure of JAK2 complexed with a potent quinoxaline ATP site inhibitor | 3krr | 0.48 |
| 2 | 1k3 | JAK2 kinase (JH1 domain) in complex with compound 9 | 4jia | 0.6 |
| 3 | jzh | Janus Kinase 2 Inhibitors | 3jy9 | 1 |
| 4 | 6tp | co-crystal structure of Jak2 with thienopyridine 19 | 3tjd | 1 |
| 5 | 50v | CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE | 5cf8 | 1.1 |
| 6 | l0i | Structure determination of Aurora Kinase in complex with inhibitor | 2w1i | 1.2 |
| 7 | j2i | Structure of Janus kinase 2 with a pyrrolotriazine inhibitor | 3q32 | 1.8 |
| 8 | 467 | Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases | 4yth | 2 |
| 9 | o19 | Aminoalkylpyrimidine Inhibitor Complexes with JAK2 | 4bbf | 2.2 |
| 10 | 4ok | CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1-CARBOXAMIDE INHIBITOR | 4zim | 2.4 |
| 11 | 50w | CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-7-[(DIMETHYL-1,3-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.02,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE | 5cf5 | 2.5 |
| 12 | az5 | Inhibitors of Jak2 Kinase domain | 2xa4 | 3 |
| 13 | 3o4 | Aminoalkylpyrimidine Inhibitor Complexes with JAK2 | 4bbe | 3.6 |
| 14 | lmm | Inhibitors of Jak2 Kinase domain | 4c61 | 4 |
| 15 | 7gy | Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin | 5tq4 | 4.2 |
| 16 | 0nv | JAK2 kinase (JH1 domain) triple mutant in complex with compound 12 | 4e6q | 4.4 |
| 17 | 17p | Crystals structure of Jak2 with a 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitor | 3rvg | 5 |
| 18 | 4hz | Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases | 4ytf | 7 |
| 19 | 953 | Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | 4d0x | 8 |
| 20 | 50o | CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-[(2S)-2,3-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-3,5,8,10-TETRAAZATRICYCLO [7.3.0.02,6]DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE | 5cf6 | 8.2 |
| 21 | 1p6 | 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2 | 3iok | 11 |
| 22 | 15v | JAK2 kinase (JH1 domain) in complex with compound 8 | 4hge | 11.9 |
| 23 | vjk | Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease | 4yti | 13 |
| 24 | 1p5 | 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2 | 3io7 | 17 |
| 25 | 7gt | Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin | 5tq7 | 21.2 |
| 26 | mi1 | Crystal structures of JAK1 and JAK2 inhibitor complexes | 3fup | 21.7 |
| 27 | bjg | Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | 4d1s | 22 |
| 28 | 7gs | Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin | 5tq8 | 23.1 |
| 29 | 0x5 | JAK2 kinase (JH1 domain) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE | 4gmy | 28 |
| 30 | 0tp | Co-crystal structure of jak2 with thienopyridine 8 | 3tjc | 31 |
| 31 | ske | JAK2 JH1 in complex with JNJ-7706621 | 5usy | 31 |
| 32 | 50y | CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE | 5cf4 | 40 |
| 33 | nvb | Crystal structure of Jak2 complexed with a potent 2,8-diaryl-quinoxaline inhibitor | 3lpb | 42 |
| 34 | 7gx | Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin | 5tq5 | 58.8 |
| 35 | 0x2 | JAK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE | 4gfm | 60 |
| 36 | ske | JAK2 JH2 in complex with JNJ-7706621 | 5usz | 106 |
| 37 | 7gv | Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin | 5tq6 | 123.6 |
| 38 | 9zs | Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model | 5wev | 150 |
| 39 | 046 | Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594 | 3ugc | 947 |
| 40 | 35r | JAK2 JH2 in complex with AT9283 | 5ut0 | 1323 |
| 41 | 2hb | Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634 | 4p7e | 1.75e+004 |
| 42 | dqx | JAK2 JH2 in complex with NVP-BSK805 | 5ut4 | 4.2e+004 |